Jaguar Health is a biopharmaceutical company dedicated to discovering, developing, and commercializing plant-based prescription medicines to address urgent global health needs. The company focuses on creating first-in-class treatments derived from natural sources, specifically targeting conditions that lack effective medical solutions. Jaguar Health operates in the global healthcare market, serving patients, healthcare providers, and pharmaceutical partners.

The company's flagship product is crofelemer, a drug extracted and purified from the bark sap of the Croton lechleri tree, commonly known as "sangre de drago." Crofelemer is currently being evaluated in a phase 3 clinical trial (OnTarget) for the preventative treatment of cancer-related diarrhea. This drug exemplifies Jaguar Health's commitment to leveraging its extensive botanical library and intellectual property portfolio to develop innovative treatments.

Jaguar Health's business model revolves around the development and commercialization of its proprietary plant-based medicines. The company generates revenue through the sale of its prescription drugs, licensing agreements, and partnerships with other pharmaceutical companies. By collaborating with local communities in South America, Jaguar Health ensures sustainable and fair-trade harvesting practices, which not only support the environment but also benefit the local economies.

In summary, Jaguar Health is a pioneering company in the biopharmaceutical industry, focusing on plant-based medicines to meet unmet medical needs. Its innovative approach, robust pipeline, and commitment to sustainability position it as a key player in the global healthcare market.

Keywords: biopharmaceutical, plant-based, prescription medicines, global health, crofelemer, cancer diarrhea, Croton lechleri, sustainable harvesting, fair trade, innovative treatments.